SCHOTT Pharma AG & Co. KGaA (1SXP) - Total Liabilities
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) has total liabilities worth €650.00 Million EUR (≈ $759.92 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 1SXP cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SCHOTT Pharma AG & Co. KGaA - Total Liabilities Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 1SXP total assets.
SCHOTT Pharma AG & Co. KGaA Competitors by Total Liabilities
The table below lists competitors of SCHOTT Pharma AG & Co. KGaA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hanon Systems
KO:018880
|
Korea | ₩6.71 Trillion |
|
Mtar Technologies Limited
NSE:MTARTECH
|
India | Rs4.30 Billion |
|
WaFd, Inc.
NASDAQ:WAFD
|
USA | $24.57 Billion |
|
KCE Electronics Public Company Limited
BK:KCE
|
Thailand | ฿4.73 Billion |
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
China | CN¥7.48 Billion |
|
LandBridge Company LLC
NYSE:LB
|
USA | $554.12 Million |
|
Coface SA
PA:COFA
|
France | €6.30 Billion |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
|
USA | $116.94 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down SCHOTT Pharma AG & Co. KGaA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1SXP net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SCHOTT Pharma AG & Co. KGaA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual total liabilities of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €650.00 Million ≈ $759.92 Million |
+20.45% |
| 2023-06-30 | €539.65 Million ≈ $630.91 Million |
+10.71% |
| 2022-06-30 | €487.46 Million ≈ $569.89 Million |
+52.10% |
| 2021-06-30 | €320.48 Million ≈ $374.67 Million |
+14.31% |
| 2020-06-30 | €280.36 Million ≈ $327.77 Million |
-- |
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more